# US 2025/0243174 A1 · Antitumoral compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0243174 A1
- Document ID: US20250243174A1
- Status: Published application
- Kind: A1
- Application number: 18/703,356
- Filed: 2022-10-21
- Published: 2025-07-31
- Earliest claimed: 2021-10-21
- Assignees: Pharma Mar, S.A.
- Applicants: Pharma Mar, S.A.
- Inventors: María Cristina MATEO URBANO; Alberto RODRÍGUEZ VICENTE; Juan HERNANDO GARCÍA; Andrés Manuel FRANCESCH SOLLOSO; Pablo Manuel AVILÉS MARÍN; María José GUILLÉN NAVARRO; María del Carmen CUEVAS MARCHANTE
- Web page: https://patentgrep.com/patent/US20250243174A1

## CPC

- C07D 309/32: having two double bonds between ring members or between ring members and non-ring members
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound of general formula (I), wherein X takes various meanings, for use in the treatment of cancer.

## Claims

### Claim 1

A compound of formula I:
wherein X=F or Me.

### Claim 2 (depends on 1)

The compound according to claim 1 of formula II:

### Claim 3 (depends on 1)

The compound according to claim 1 of formula III:

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 4)

A dosage form comprising a pharmaceutical composition according to claim 4.

### Claim at position 6

-9. (canceled)

### Claim 10 (depends on 1)

A method of treating cancer in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to claim 1; wherein the cancer is a solid tumor and is selected from lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, pancreatic cancer and gastric cancer.

### Claim 11 (depends on 1)

A method of inhibiting cancer cell growth, comprising contacting cancer cells with a compound claim 1; wherein the cancer cell is a solid tumor and is selected from lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, pancreatic cancer and gastric cancer.

### Claim 12 (depends on 1)

A kit comprising a therapeutically effective amount of a compound according to claim 1.

### Claim 13 (depends on 12)

The kit according to claim 12 further comprising instructions for use of the compound in the treatment of cancer that comprises a solid tumor and is selected from lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, pancreatic cancer and gastric cancer.

### Claim 14

A process for the manufacture of a compound of formula I, comprising reacting a compound of formula V with a suitable reagent for the synthesis of carbamates to give a compound of formula I
wherein X=F or Me.

### Claim 15

An intermediate compound of formula V, VII, IX or XI, useful for the manufacture of a compound of formula I
wherein R3 is an unsubstituted C1-C4 alkyl group, ProtOH is a protecting group for hydroxy and X is as defined for formula I.

### Claim 16 (depends on 15)

The intermediate compound according to claim 15 of formula V
wherein X=F or Me.

### Claim 17 (depends on 4)

A method of treating cancer in a patient in need thereof, comprising administering to said patient a pharmaceutical composition according to claim 4; wherein the cancer is a solid tumor and is selected from lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, pancreatic cancer and gastric cancer.

### Claim 18 (depends on 5)

A method of treating cancer in a patient in need thereof, comprising administering to said patient a dosage form according to claim 5; wherein the cancer is a solid tumor and is selected from lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, pancreatic cancer and gastric cancer.

### Claim 19 (depends on 4)

A method of inhibiting cancer cell growth, comprising contacting cancer cells with a pharmaceutical composition according to claim 4; wherein the cancer is a solid tumor—and is selected from lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, pancreatic cancer and gastric cancer.

### Claim 20 (depends on 5)

A method of inhibiting cancer cell growth, comprising contacting cancer cells with a dosage form according to claim 5; wherein the cancer cell is a solid tumor and is selected from lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, pancreatic cancer and gastric cancer.

### Claim 21 (depends on 4)

A kit comprising a pharmaceutical composition according to claim 4.

### Claim 22 (depends on 21)

The kit according to claim 21 further comprising instructions for use of the pharmaceutical composition in the treatment of cancer comprising a solid tumor and is selected from lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, pancreatic cancer and gastric cancer.

### Claim 23 (depends on 5)

A kit comprising a dosage form according to claim 5.

### Claim 24 (depends on 23)

The kit according to claim 23 further comprising instructions for use of the dosage form in the treatment of cancer that comprises a solid tumor and is selected from lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, pancreatic cancer and gastric cancer.
